Diabetes Knowledge into Practice Podcast
Liberum IME
A summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge into Practice (https://diabetes.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.
Categories: Health
Listen to the last episode:
Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease.
For more free education, go to diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.
Faculty disclosures
Prof. Francesco Giorgino
Grants or contracts: Eli Lilly, Roche Diabetes Care
Consulting: Eli Lilly, Novo Nordisk
Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim
Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune
Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE
Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk
Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi
Dr. Darren K. McGuire
Clinical trial leadership:
- Former: Esperion, AstraZeneca, CSL Behring
- Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam
Consultancy:
- Former: Merck & Co
- Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics
Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Previous episodes
-
110 - Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk Wed, 14 Feb 2024
-
109 - Effective strategies for encouraging behaviour change Wed, 14 Feb 2024
-
108 - World Diabetes Day – Overcoming Cultural Obstacles to Personalise Diabetes Care  Tue, 19 Dec 2023
-
107 - Congress special: Highlights from EASD 2023  Mon, 11 Dec 2023
-
106 - Striving for Balance: Achieving Glycemic, Weight, and Cardiorenal Targets in T2D Care Thu, 28 Sep 2023
-
105 - Highlights from ADA 2023 Tue, 12 Sep 2023
-
104 - Conference special: EASD 2022 Highlights | With Prof. Apostolos Tsapas  Mon, 14 Nov 2022
-
103 - Publication special: Data from the SURPASS program | With Prof Carol Wysham  Tue, 27 Sep 2022
-
102 - Tailoring GLP-1 RA dosing regimens | With Dr Harpreet Bajaj Mon, 12 Sep 2022
-
101 - Focus on CKD: Latest guidelines and therapies | With Dr David Cherney  Mon, 22 Aug 2022
-
100 - Focus on CVD: How much do we know now? | With Prof. Naveed Sattar Fri, 12 Aug 2022
-
99 - Advances in incretin therapy: dual agonists and beyond | With Prof. Filip Knop Fri, 15 Jul 2022
-
98 - Latest approaches to supporting weight loss in T2D | With Dr Robert Kushner  Fri, 01 Jul 2022
-
97 - Conference special: ADA 2022 | With Prof. Jennifer Green Fri, 17 Jun 2022
-
96 - NASH: Current and future therapies | With Prof. Philip Newsome Tue, 07 Jun 2022
-
95 - Publication special: SUSTAIN FORTE | With Dr Juan Pablo Frías Wed, 01 Jun 2022
-
94 - Latest data on SGLT2is in heart failure | With Prof. Javed Butler  Thu, 19 May 2022
-
93 - Closeup on the ADA 2022 Standards of Medical Care | With Prof. Anne Peters  Mon, 16 May 2022
-
92 - NASH: Advances in non-invasive screening | With Dr Kenneth Cusi  Mon, 16 May 2022
-
91 - Update on Covid-19 and diabetes: What more do we know? | With Prof. Partha Kar  Wed, 13 Apr 2022
-
90 - NASH: What’s behind the link with T2D and obesity? | With Prof. Giulio Marchesini  Fri, 01 Apr 2022
-
89 - NASH: Pathogenesis and pathophysiology | With Prof. Zobair Younossi Tue, 01 Mar 2022
-
1 - About this podcast Wed, 26 Jun 2019